Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 20, 2022, Kintara Therapeutics, Inc. (the "Company") and Saiid Zarrabian, the Company's Head of Strategic Partnerships and a member of the Board of Directors (the "Board") of the Company, mutually agreed that Mr. Zarrabian would step down from his role as Head of Strategic Partnerships and as a member of the Board, effective as of May 23, 2022 (the "Separation Date") to pursue other opportunities. Mr. Zarrabian's separation was not the result of any disagreements with the Company relating to the Company's operations, policies or practices.

In connection with Mr. Zarrabian's separation from the Company, on May 20, 2022, the Company and Mr. Zarrabian entered into a separation and general release agreement (the "Separation Agreement"). The Separation Agreement provides, among other things, for Mr. Zarrabian to receive the following:

•

continued payments of nine months of his annual base salary, equal to the sum of $213,750, commencing on the first regular payroll date that is after the Separation Date and paid in installments in accordance with the Company's regular payroll practices;

•

a one-time bonus payment of $24,826.67 in connection with his service as the Company's Head of Strategic Partnerships to be paid on the Separation Date;

•

reimbursement of healthcare coverage payments for a period of up to nine months following the Separation Date;

•

continued payments of life insurance premiums for a period of up to nine months following the Separation Date; and

•

an additional six months of service vesting credit for each of his stock options outstanding as of the Separation Date, and all of his vested stock options, including any options so accelerated, remaining exercisable for up to a nine-month period measured from the Separation Date (or earlier expiration of the option's term).

The Separation Agreement further provides for general release and non-disparagement provisions in favor of the Company. In addition, Mr. Zarrabian will be subject to non-solicitation provisions, which will apply for a period of twelve months following the Separation Date.

The foregoing description of the Separation Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of such agreement, a copy of which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits.

Exhibit No.       Description

10.1                Separation and General Release Agreement between the Company and
                  Saiid Zarrabian, dated May 20, 2022.

104               Cover Page Interactive Data File (embedded within the Inline XBRL
                  document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses